Millions of people take gabapentin believing it is simply another medication to ease persistent nerve pain, sciatica, shingles, or chronic back problems. For many, it becomes part of everyday life—a prescription renewed almost automatically because it seems to help them function. But a new study is prompting doctors and patients alike to ask a difficult question: could long-term use carry risks that extend far beyond pain management?
Researchers at Case Western Reserve University analyzed more than 26,000 medical records in an effort to better understand the long-term effects associated with gabapentin use. Their findings drew attention to a concerning pattern. Individuals who had received six or more gabapentin prescriptions were found to have a 29% higher likelihood of later developing dementia compared with those who had not reached that level of exposure. While the study identified an association rather than proof of cause and effect, the results were significant enough to fuel renewed discussion about how the medication is prescribed and monitored.
That distinction is critically important.
An increased risk observed in an observational study does not necessarily mean the medication itself causes dementia. Many factors can influence the outcome of this kind of research, and people taking gabapentin often differ from those who are not in ways that may also affect brain health. Even so, when a widely prescribed medication is linked to a measurable increase in risk, researchers believe the findings deserve careful attention rather than dismissal.
Gabapentin has become a common treatment for nerve-related pain because it can provide meaningful relief for conditions that are otherwise difficult to manage. People living with diabetic neuropathy, postherpetic neuralgia, spinal nerve injuries, and other chronic pain disorders may rely on the medication to sleep, move more comfortably, and regain some quality of life. For many patients, it has been an important therapeutic option when alternatives are limited or carry their own significant risks.
Yet chronic pain itself is far from harmless.
Medical experts have long recognized that persistent pain can affect much more than the body. Living with continuous discomfort often leads to poor sleep, reduced physical activity, depression, anxiety, and social isolation. Each of these factors has independently been associated with changes in cognitive function and, in some studies, an increased risk of dementia. That reality makes it especially challenging to determine whether the medication, the underlying condition, or a combination of both contributes to the observed relationship.
Because of this complexity, specialists are urging caution—not alarm.
The findings should not be interpreted as a reason for patients to abruptly stop taking gabapentin, particularly if it is effectively controlling symptoms. Suddenly discontinuing the medication without medical supervision can lead to withdrawal symptoms and other health complications. Instead, healthcare professionals recommend using the study as an opportunity for informed conversations between patients and their prescribing clinicians.
Those discussions may include questions such as whether the current dose remains appropriate, whether the medication is still providing meaningful benefit, and whether other treatment options could be considered. Depending on the individual, alternatives might include physical therapy, targeted exercise programs, behavioral pain management techniques, other medications, or a combination of approaches designed to reduce reliance on long-term drug therapy.
The broader message extends beyond gabapentin alone.
Every medication involves weighing potential benefits against possible risks. What works well for one patient may not be the best choice for another, especially when treatment continues for months or years. Regularly reviewing medications, reassessing symptoms, and adjusting treatment plans as health changes are essential parts of good medical care.
This new research also highlights the importance of continued investigation. Studies like this are designed to identify patterns that warrant further exploration, not to deliver final answers. Additional research will be needed to determine whether the observed association reflects a direct effect of gabapentin, the impact of chronic pain itself, or other underlying factors that were not fully captured in the analysis.
For patients currently taking gabapentin, the most appropriate response is neither fear nor complacency. It is informed awareness. Rather than viewing the medication as entirely harmless or inherently dangerous, individuals should feel empowered to ask questions, review their treatment with their healthcare provider, and make decisions based on their own medical history and circumstances.
Ultimately, the study serves as a reminder that managing chronic pain is rarely a simple choice. Relief from persistent suffering can dramatically improve daily life, but long-term treatment should always be balanced with ongoing evaluation of potential risks. The goal is not simply to reduce pain today—it is to protect overall health for the years ahead. Thoughtful prescribing, regular follow-up, and open communication between patients and clinicians remain the strongest tools for achieving both.
